4Edmond MB,Wallace SE,McClish DK,et al,Nosocomial blood-stream infectious in United States hospitals:a three-year analysis[J].Clin Infect Dis,1999,29(2)∶239-244.
5Kauffman CA,Carrer PL.Antifungal agents in the 1990s.Current status and future developments[J].Drugs,1997,53(4)∶539-549.
6Pfaller MA,Messer SA,Hollis RJ,et al.Antifungal activities of posaconazole,ravuconazole,and voriconazole compared to those of itraconazole and amphotericin B,against 239 clinical isolates of asppergillus spp,and other Filamentous fungi:report from SENTRY antimicrobial surveillance program,2000[J].Antimicrob Agents Chemotherapy,2002,46 (4):1032 -1037.
7Kauffman CA,Carrer PL.Antifungal angents in the 1990s.Current status and future developments[J].Drugs,1997,53(4):539 -549.
8Caillot D,Bassaris H,McGeer A,et al.Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergllosis in patients with hematologic malignancies,chronic granulomatous distrase,or AIDS[J].Clin Infect Dis,2001,33 (8):83-90.
9Winston DJ,Maziarz RT,Chandrasekar PH,et al.Intravenous and oral itraconazole versus intravenous and oral fluconazole for long -term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients.A multicenter,randomized trial[J].Ann Intern Med.2003,138 (9):705 -713.
10Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis, 2002, 34: 7-14.
